Faron, etusivu

Tiedotteet ja julkaisut

Faron Pharmaceuticals julkistaa tiedotteensa englannin kielellä.

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Regulatory

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Regulatory

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Faron Pharmaceuticals Ltd: Grant of Options

Insider Transaction Regulatory

Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session

Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025

Holding in Company

Regulatory
Next
Siirry takaisin sivun alkuun